Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
combination drug
|
| gptkbp:approvalYear |
1999
|
| gptkbp:ATCCode |
gptkb:P01BF01
|
| gptkbp:brand |
gptkb:Coartem
gptkb:Riamet |
| gptkbp:contains |
gptkb:artemether
gptkb:lumefantrine |
| gptkbp:contraindication |
hypersensitivity to artemether
severe malaria hypersensitivity to lumefantrine |
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:drugClass |
antimalarial
|
| https://www.w3.org/2000/01/rdf-schema#label |
artemether-lumefantrine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits parasite growth
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
sleep disorders
abdominal pain dizziness headache loss of appetite palpitations |
| gptkbp:usedFor |
malaria
Plasmodium falciparum infection |
| gptkbp:usedIn |
gptkb:Africa
gptkb:Asia gptkb:South_America |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:artemisinin_combination_therapy
gptkb:artemether |
| gptkbp:bfsLayer |
6
|